Multiple sclerosis

New help, new hope

David C Hess, Mary D. Hughes

Research output: Contribution to journalReview article

Abstract

Immunomodulatory agents reduce the rate of relapse in patients with relapsing-remitting multiple (MS); in addition, these drugs, particularly the interferons, can slow the progression of the disease. Thus, early treatment can help prevent disability. High doses of corticosteroids given early during an MS relapse may decrease the length and severity of the attack. Mitoxantrone is generally reserved for patients with progressive forms of MS who are experiencing rapid loss functioning. Consider intravenous immunoglobulin for patients who have had steady disease progression. Combinations of either an interferon or glatiramer with oral immunosuppresant or pulse corticosteroid therapy are increasingly used.

Original languageEnglish (US)
Pages (from-to)1144-1148
Number of pages5
JournalConsultant
Volume45
Issue number10
StatePublished - Sep 1 2005

Fingerprint

Multiple Sclerosis
Interferons
Disease Progression
Adrenal Cortex Hormones
Recurrence
Mitoxantrone
Intravenous Immunoglobulins
Therapeutics
Pharmaceutical Preparations
Glatiramer Acetate

Keywords

  • Immunomodulatory therapy
  • Multiple sclerosis
  • Rehabilitation

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Hess, D. C., & Hughes, M. D. (2005). Multiple sclerosis: New help, new hope. Consultant, 45(10), 1144-1148.

Multiple sclerosis : New help, new hope. / Hess, David C; Hughes, Mary D.

In: Consultant, Vol. 45, No. 10, 01.09.2005, p. 1144-1148.

Research output: Contribution to journalReview article

Hess, DC & Hughes, MD 2005, 'Multiple sclerosis: New help, new hope', Consultant, vol. 45, no. 10, pp. 1144-1148.
Hess DC, Hughes MD. Multiple sclerosis: New help, new hope. Consultant. 2005 Sep 1;45(10):1144-1148.
Hess, David C ; Hughes, Mary D. / Multiple sclerosis : New help, new hope. In: Consultant. 2005 ; Vol. 45, No. 10. pp. 1144-1148.
@article{c286d32c2faa44d1aacf8f7474c76a51,
title = "Multiple sclerosis: New help, new hope",
abstract = "Immunomodulatory agents reduce the rate of relapse in patients with relapsing-remitting multiple (MS); in addition, these drugs, particularly the interferons, can slow the progression of the disease. Thus, early treatment can help prevent disability. High doses of corticosteroids given early during an MS relapse may decrease the length and severity of the attack. Mitoxantrone is generally reserved for patients with progressive forms of MS who are experiencing rapid loss functioning. Consider intravenous immunoglobulin for patients who have had steady disease progression. Combinations of either an interferon or glatiramer with oral immunosuppresant or pulse corticosteroid therapy are increasingly used.",
keywords = "Immunomodulatory therapy, Multiple sclerosis, Rehabilitation",
author = "Hess, {David C} and Hughes, {Mary D.}",
year = "2005",
month = "9",
day = "1",
language = "English (US)",
volume = "45",
pages = "1144--1148",
journal = "Consultant",
issn = "0010-7069",
publisher = "Cliggott Publishing Co.",
number = "10",

}

TY - JOUR

T1 - Multiple sclerosis

T2 - New help, new hope

AU - Hess, David C

AU - Hughes, Mary D.

PY - 2005/9/1

Y1 - 2005/9/1

N2 - Immunomodulatory agents reduce the rate of relapse in patients with relapsing-remitting multiple (MS); in addition, these drugs, particularly the interferons, can slow the progression of the disease. Thus, early treatment can help prevent disability. High doses of corticosteroids given early during an MS relapse may decrease the length and severity of the attack. Mitoxantrone is generally reserved for patients with progressive forms of MS who are experiencing rapid loss functioning. Consider intravenous immunoglobulin for patients who have had steady disease progression. Combinations of either an interferon or glatiramer with oral immunosuppresant or pulse corticosteroid therapy are increasingly used.

AB - Immunomodulatory agents reduce the rate of relapse in patients with relapsing-remitting multiple (MS); in addition, these drugs, particularly the interferons, can slow the progression of the disease. Thus, early treatment can help prevent disability. High doses of corticosteroids given early during an MS relapse may decrease the length and severity of the attack. Mitoxantrone is generally reserved for patients with progressive forms of MS who are experiencing rapid loss functioning. Consider intravenous immunoglobulin for patients who have had steady disease progression. Combinations of either an interferon or glatiramer with oral immunosuppresant or pulse corticosteroid therapy are increasingly used.

KW - Immunomodulatory therapy

KW - Multiple sclerosis

KW - Rehabilitation

UR - http://www.scopus.com/inward/record.url?scp=29644434383&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=29644434383&partnerID=8YFLogxK

M3 - Review article

VL - 45

SP - 1144

EP - 1148

JO - Consultant

JF - Consultant

SN - 0010-7069

IS - 10

ER -